Monday, October 29, 2012

Texas Governor Rick Perry & GenNXeix Biotech Inc CIO Rose Conrad Reports that Breast Cancer Stem Cells Treatments are here to stay


Barron’s Medical Journal Reporting From Houston’s MD Anderson In The Houston Medical Center
Texas Governor Rick Perry & GenNXeix Biotech Inc CIO Rose Conrad Reports that Breast Cancer Stem Cells Treatments are here to stay

Houston ( AP ) GenNXeix Biotech Inc CIO Rose Conrad Reports that Breast Cancer Stem Cells Treatments are here to stay. Governor Rick Perry at the Houston Stem Cell Summit. Houston Stem Cell Summit is one of the largest and most informative events of its kind in the United States. This event brings together researchers and business lead

ers from across the spectrum of industries involved in adult stem cell research, discussing academic advancements, therapies, patient experiences and the evolving regulatory and business climates surrounding stem cell applications. Over the past 36 months alone, researchers at Texas facilities ranging from the Texas Heart Institute to the M.D. Anderson Cancer
Center to Baylor University have published more than 100 peer-reviewed stem cell studies. Looking back to the beginning of 2000, that number grows to more than 500. We've also been bringing some of the greatest names in stem cells to Texas, including Dr. Doris Taylor, formerly of the University of Minnesota, whose notable accomplishments include growing a human heart in a lab using adult stem cells. She joins a healthy and growing population of some of the most innovative scientists in the country, including
Dr. Darwin Prockop and his team from Tulane University, who now call Texas home. These experts are also drawn by Texas' high quality of life, strong economy and our state's dedication to investing in the technologies of the future via initiatives like the Cancer Prevention Research Institute of Texas (CPRIT) and our Emerging Technology Fund (ETF). CPRIT has directly funded more than $11 million for the study of adult stem cells and regenerative medicine. The ETF, meanwhile, has invested more than $194 million in grant matching and research superiority funds in Texas universities, helping secure quality facilities and, more importantly, quality researchers and their staffs. This sort of cutting-edge research is a perfect fit for Texas, which has long been a place where people with game-changing ideas come to make their marks on the world. They come to Texas because, like everyone, they see a place with low taxes, fair courts, reasonable regulation and a work force that can meet any and all challenges you can throw at it.
Brought To You By gloStream
This summer, I was invited to Boston to discuss Texas' top ranking in the creation of biotech jobs, another sign that the Lone Star State is the place where high-tech visionaries of all types are planting their flags. However, very few of these fields are more promising, or important, than this one. Adult stem cell research can change the world through regenerative medicine and its untapped potential to tackle some of the most challenging diseases known to man. In Austin, we're taking steps to
clear the way to advance this research as quickly and safely as possible. Earlier this year, the Texas Legislature, Texas Medical Board and Texas Health and Human Services Commission worked to make it easier for companies, institutions and physicians to work together in the interest of safe, effective and ethical adult stem cell research. This is an important time for the field of regenerative medicine, and I'm proud and excited that Texas is playing a key role in its advancement. Adult stem cell research and therapies are promising for patients and the Texas economy alike. As with any pioneering technology, there will be both success and setbacks as we move forward. However, I am committed to making Texas the nation's center for regenerative medicine, and transforming the promise of adult stem cell therapy into a new and exciting reality. GenNXeix Biotech Inc. Multiple genes with weaker individual effects--acting together--probably influence an individual's risk of familial testicular cancer. 90% of the 8,400 new cases of testicular cancer diagnosed this year is Germ Cancer. The cyclic AMP pathway is the Key to treating Testicular Cancer. There ar3 Ready Available Drugs on the market that target the PDE11A Gene. If you have strong candidate in your family for this gene, mutation and trait the Healthcare Bill in the 111th Congress is will extend the life of Americans with Familial Testicular Germ Cell

Tuesday, October 23, 2012

GenNXeix Medical Systems Announced Today: Out-Souring Of Electronic Medical Records With Our Staff Working From Your Location … Doctors


Press Release: < Presswire >
New York City New York Barron Medical Journal Reporting:
October 23, 2012 GenNXeix Medical Systems Announced Today: Out-Souring Of Electronic Medical Records With Our Staff Working From Your Location … Doctors Press Release:
EHR Service Level Agreement
Purpose

New York ( AP ) Gennxeix Medical System Announced Today Outsourcing of Electronic Medical R

ecords from your location Doctors. Gennxeix The purpose of the GenNXeix Medical System Electronic Medical Record ("EHR") Service Level Agreement ("SLA") is to formalize our commitment to our valued health care professional users ("Clients"). Our SLA is i
ntended to memorialize the specific level of support that we promise to provide to our Clients. This SLA may evolve over time, with additional knowledge of our Clients requirements, as well as the introduction of new application and services into the support portfolio, so please continue to check back for updates.
Definitions The following definitions shall apply to the GenNXeix Medical System EHR SLA. "Downtime" means, for the EHR, if there is more than a five percent (5%) of the user community issue rate. Downtime is measured based on server side issue rate. "Downtime Period" means, for the EHR, a period of ten consecutive minutes of Downtime. Intermittent Downtime for a period of less than ten minutes will not be counted towards any Downtime Periods.
Brought To You By gloStream
"GenNXeix Medical System EHR Covered Services" means the GenNXeix Medical System Electronic Medical Record and Practice Management Service. This does not include the GenNXeix Medical System website, support site, or any other additional Gennxeix Medical Systems, Inc. branded site that does not pertain directly to the EHR system. "Monthly Uptime Percentage" means total number of minutes in a calendar month minus the number of minutes of Downtime suffered from all Downtime Periods in a calendar month, divided by the total number of minutes in a calendar month. "Scheduled Downtime" means those times where Gennxeix Medical Systems, Inc. notifies Client of periods of Downtime at least twenty four hours prior to the commencement of
such Downtime. There will be no more than thirty six hours of Scheduled Downtime per calendar year. Scheduled Downtime is not considered Downtime for purposes of this GenNXeix Medical System EHR SLA, and will not be counted towards any Downtime Periods. "Service" means the service provided by Gennxeix Medical Systems, Inc. to Clients under the applicable GenNXeix Medical System EHR Agreement. "Service Credit" means the following: Monthly Uptime Percentage Days of Service added to the end of the Service term, at no charge < 99.9% - ≥ 99.0% 3 < 99.0% - ≥ 95.0% 7 < 95.0% 15 Scope of Agreement During the term of the applicable GenNXeix Medical System EHR SLA, the GenNXeix Medical System EHR Covered Services web interface will be operational and available to Clients at least 99.9% of the time, excluding scheduled downtime, in any calendar month (the "GenNXeix Medical System EHR SLA"). If Gennxeix Medical Systems, Inc. does not meet the GenNXeix Medical System EHR SLA, and if Client meets its obligations under this GenNXeix Medical System EHR SLA, Client will be eligible to receive the Service Credits described below. This GenNXeix Medical System EHR SLA states Client's sole and exclusive remedy for any failure by Gennxeix Medical Systems, Inc. to provide the Services covered by this SLA. Client Responsibilities The Client has the following general responsibilities under this SLA: • The Client will conduct business in a courteous and professional manner with Gennxeix Medical Systems, Gennxeix Medical Systems, Inc. • The Client must notify Gennxeix Medical System, Inc. and request the Service Credit within thirty days (30) from the time the Client becomes eligible to receive the Service Credit. • Service credit is only available to Clients who are actively enrolled in the paid subscription version of the GenNXeix Medical System EHR service. Failure to comply with these few responsibilities will forfeit Client’s right to receive a Service Credit. Maximum Service Credit The aggregate maximum number of Service Credits to be issued by Gennxeix Medical Systems Inc. to Client for any and
all Downtime Periods that occur in a single calendar month shall not exceed fifteen days (15) of Service to be added to the end of Client’s term for the Service. Service Credits may not be exchanged for, or converted to, monetary amounts.
Exclusions The GenNXeix Medical System EHR SLA does not apply to any service s that expressly exclude this GenNXeix Medical System EHR SLA (as stated in the documentation for such services) or any performance issues: (i) caused by factors outside of Gennxeix Medical Systems Inc’s reasonable primary control, including without limitation, acts of God, acts of government, flood, fire, earthquakes, civil unrest, acts of terror, strikes or other labor problems (other than those involving GenNXeix Medical System employees), or Internet service provider failures or delays, and; (ii) that resulted from Client’s equipment or third party equipment, or both (not within the primary control of Gennxeix Medical Systems Inc).
Contact Information For any questions, concerns or requests for Service Credits please contact GenNXeix Medical Systems, Inc. by submitting a request Gennxeix1@Gmail.com or Call 281.661.6002

Friday, October 19, 2012

How Many Women Get Breast Cancer and What Are We Doing About It:


Barron’s Medical Journal Reporting from Prairie View A&M University School of Nursing, Houston Medical Center Houston, Texas
How Many Women Get Breast Cancer and What Are We Doing About It:

Houston ( AP ) Barron’s Medical Journal and The American Cancer Society’s most recent estimates for breast cancer in the United States are for 2012: • About 226,870 new cases of invasive breast cancer in women • About 63,300 new c

ases of carcinoma in situ (CIS) will be found (CIS is non-invasive and is the earliest form of breast cancer). • About 39,510 deaths from breast cancer (women) Breast cancer is the most common cancer among women in the United States, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer.
Brought To You By Antiques of River Oaks Houston,Tx The chance of a woman having invasive breast cancer some time during her life is about 1 in 8. The chance of dying from breast cancer is about 1 in 36. Breast cancer death rates have been going down. This is probably the result of finding the cancer earlier and better treatment. Right now there are more than 2.9 million breast cancer survivors in the United States.

Genomics Science:

One woman’s breast cancer may have different genetic drivers from another woman’s and, in fact, may have more in common with prostate cancer in a man or another patient’s lung cancer. Gennxeix Biotech breast cancer researchers is a company work product that find genes

that might be causing an individual’s cancer to grow, to analyze genetic data and to find and test new drugs directed against these genetic targets. Leading venture capital firms are involved. Under this new Genomics approach, researchers expect that treatment will be tailored to an individual tumor’s mutations, with drugs, eventually, that hit several key aberrant genes at once.

Breast Cancer Gene Finding System:

illumina MiSeq is the only fully integrated personal sequencer, delivering a streamlined solution that takes you from rapid sample prep through automated data analysis and storage in the Base Space cloud. Sequencing doesn’t get any easier than this. The Ion Proton™ Sequencer, is based on the next generation of semiconductor sequencing technology that has made its predecessor, the Ion Personal Genome Machine™ (PGM™), the fastest-selling sequencer in the world. Up to now, it has taken weeks or months to sequence a human genome at a cost of $5,000 to $10,000 using optical-based sequencing technologies. The slow pace and the high instrument cost of $500,000 to $750,000 have limited human genome sequencing to relatively few research labs. Baylor College of Medicine, Yale School of Medicine, and The Broad Institute, have each signed up for multiple Ion Proton™Sequencers and will be the first customers to adopt this transformative technology.

Companies that are making a difference in Breast Cancer: BGI Americas:
BGI Americas, headquartered in Cambridge, MA, was founded in 2010. BGI Americas has established partnerships and collaborations with leading American academic and governmental research institutions as well as global biotechnology and pharmaceutical companies. Among the more recent partnerships and collaborations entered into by BGI Americas include:

• Partnership with Children’s Hospital of Philadelphia, BGI@CHOP, to conduct large-scale human genome sequencing and bioinformatics analysis at a newly established, state-of-the-art Joint Genome Center at CHOP.
OPKO Health: < HR > OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization expertise to pursue acquisitions of commercial businesses that will both drive our growth and provide geographically diverse sales and distribution opportunities. We have and may continue to make investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.
Gennxeix Biotech Inc:
Gennxeix Biotech Software Inc Genomics we are creating genomic-driven commercial solutions to revolutionize many industries. We have started by focusing on energy, but we imagine a future where our science could be used to produce a variety of products, from synthetically derived vaccines to prevent human diseases to efficient cost effective ways to create clean drinking water. The world is dependent on science and we're leading the way in turning novel science into life-changing solutions. What these companies are doing is taking medicine to the next level. From Alzheimer , Breast Cancer to Diabetes they are using your genes to determined if you have one or many diseases. This Process is called Genomics. Yes we are in the genomics revaluation. We know with breast cancer up to 50 percent of the patients get chemotherapy that do not need. In stead of lumping treatment decisions in to one modis of care Doctors now can pin point to a Cure. A example of this discovery of the genes that contribute to these pathophysiologies when deregulated by recurrent aberrations is important to understanding mechanisms of cancer formation and progression and to guide improvements in cancer diagnosis and treatment. Electronic Medical Records Gennxeix is also key in a cure for breast cancer. What the fust is all about is scientist recognized something call Luminal subtypes. Luminal subtypes had the lowest overall mutation rate, but by contrast, had the largest number of genes observed to be significantly mutated. This suggests that each of the genes identified as significantly mutated in the Luminal subtypes is more likely to be important in fueling cancer progression. The Luminal subtypes are characterized by the specific expression signature of multiple so-called transcription-factor genes, including ESR1, GATA3, FOXA1, XBP1 and cMYB. These genes have a complex interaction, cooperating in an orchestrated series of activations. GATA3 and FOXA1 are frequently mutated, but those mutations are mutually exclusive, meaning that mutations were observed in eitherGATA3 or FOXA1 but never in both. However, ERS1 and XBP1 are highly expressed but infrequently mutat. With Genomics we can separate breast cancer genes and break in to categories the different types of breast cancers. 1 Hormone receptor-positive disease, or tumors that have receptors for hormones on the surface of their cells, meaning those tumors can be treated with hormone-targeted therapy. 1 HER2-positive, referring to the over-expression of the gene HER2, a type of protein that can also be targeted. 1 "Triple-negative" disease, which lacks the hormone receptors - estrogen and progesterone - as well as the HER2 genes that are targeted by some of the newest, most successful treatments. Gennxeix discovered that some patients with HER2-positive breast cancer tended not respond to HER2-targeted therapies. Also, some
patients with triple-negative breast cancers responded to therapies while others didn't. "We have been lumping things together that shouldn't be lumped together The new classifications - four types called HER2 "enriched," luminal A, luminal B and basal-like - categorize breast cancers by their genomic structure using a dizzying array of data points not previously available that have identified new pathways for the cancer to do its damage, making it possible for researchers to identify new places to target disease. What could be seen as the most promising development of this breast cancer study, researchers determined that some basal-like cancers had more in common with an aggressive form of ovarian cancer known as "serous" than with other types of breast cancer. Two other types of breast cancer, accounting for most cases of the disease, arise from the luminal cells that line milk ducts. These cancers have proteins on their surfaces that grab estrogen, fueling their growth. Just about everyone with estrogen-fueled cancer gets the same treatment. Some do well. Others do not. The genetic analysis divided luminal cancers into two distinct subtypes. The luminal A subtype had good prognoses while luminal B did not, suggesting that perhaps patients with luminal A tumors might do well with just hormonal therapy to block estrogen from spurring their cancers while luminal B patients might do better with chemotherapy in addition to hormonal therapy. In some cases, genetic aberrations were so strongly associated with one or the other luminal subtype that they appeared to be the actual cause of the cancer. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Gennxeix Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Gennxeix also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients. formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts. Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma Gennxeix works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients response differently. Genomics is the GPS to Extend life in Breast Cancer Patients. President Obama Affordable Care Acts get’s a Cure

Friday, October 12, 2012

Congresswoman Sheila Jackson Lee Says Electronic Medical Records Are Mandatory And Missing From The Obama-Care Debate


Barron's Medical Journal Reporting From Congresswoman Sheila Jackson Lee"Empower Your Health & Live Healthy Today Health Fair" George R. Brown Convention Houston Texas
Congresswoman Sheila Jackson Lee Says Electronic Medical Records Are Mandatory And Missing From The Obama-Care Debate

Houston ( AP ) Obama - Care is a effective weapon when used with Electronic Medical Records (EMR). Barron’s Medical Journal Interviews Rose Conrad the Global CEO of Gennxeix Medical systems and we are happy to report that Dr. Conrad says with EMR

President Obama Health Care plan will save Billions. Doctors that are getting Medicaid and Medicare will have be online cutting out all the waste that a paper base medical practice management systems provide. Conrad also says that the technical barriers and costs are holding back electronic sharing of clinical data, according to the results of a recent survey conducted by a consortium of physician associations.
Brought To You By gloStream
More than 70% of the physicians polled said that their electronic health record (EHR) system was unable to communicate electronically with other systems – a lack of
interoperability that prevents electronic exchange of information. Another barrier is the cost of setting up and maintaining interfaces and exchanges to share information. The Bipartisan Policy Center in Washington highlights the progress that physicians have made in embracing EHRs. Several years ago, this type of survey might have shown that physicians wanted to keep the status quo or that they feared change, he said. Now, the barriers to exchanging information have more to do with technology than physician attitudes. M
aking progress on interoperability will be essential as physicians move forward with different care delivery models such as the patient-centered medical home and the medical home neighborhood, which includes subspecialists, Dr. Conrad said. "
The success of these new models will depend on health IT infrastructure that supports seamless coordination of care, patient engagement, and clinical information exchange," he said. "You can’t do team-based care unless everybody has access to the information appropriately." Beyond interoperability, there are still challenges for physicians seeking to implement EHRs in their practices. The money available through the Medicare and M
edicaid Electronic Health Record Incentive Programs is beginning to change that equation, he said, but most physicians still say that the incentives offered aren’t sufficient to offset the loss in productivity, the change in their workflow, and the assorted other expenses of bringing on EHRs. "We’re still very concerned about that as a barrier," Dr. Conrad said. The physician survey was developed by the American College of Physicians and Doctors Helping Doctors Transform Health Care. The American College of Surgeons, the Association of Medical Directors of Information Systems, and the American Academy of Pediatrics also were involved with the survey. The groups circulated the survey to
thousands of their members and received responses from more than 500 physicians. About three-quarters of the respondents were using an EHR at the time of the survey, higher than the national average of about 55%, according to the National Center for Health Statistics. As a result, the survey developers cautioned that the results
should not be used to reflect the view of U.S. physicians as a whole. The respondents were mostly from small practices. Nearly three-quarters of the physicians surveyed worked in practices with 10 or fewer physicians and more than half were in practices of 5 or fewer physicians. When the Medical Community adds the synergy of Electronic Medical Records to Genomics personalize Medicine ObamaCare is a powerful Tool

Saturday, October 6, 2012

The 2012 Susan G. Komen Race for the Cure® In Houston Was The Best In The History Of The Race


Barron's Medical Journal Reporting From Down Town Houston
Houston (AP) The 2012 Susan G. Komen Race for the Cure® In Houston Was The Best In The History Of The Race. An Un-offical counts was over one hundred thousand.

With so many people participating in this years Susan G. Komen Race for the Cure® event Barron's Medical Journal Robert Reports GenNXeix Biotech CEO says that genomics and genes is what next for a breast cancer cure. The latest finding is although still in the early stages of research, molecular breast cancer subtypes may become useful in planning treatment and developing new therapies. Most studies divide breast cancer into four major molecular subtypes: Luminal A, Luminal B, Triple negative/basal-like,and HER2 type

Brought To You By gloStream

What the fust is all about is scientist recognized something call Luminal subtypes. Luminal subtypes had the lowest overall mutation rate, but by contrast, had the largest number of genes observed to be significantly mutated. This suggests that each of the genes identified as significantly mutated in the Luminal subtypes is more likely to be important in fueling cancer progression. The Luminal subtypes are characterized by the specific expression signature of multiple so-called transcription-factor genes, including ESR1, GATA3, FOXA1, XBP1 and cMYB.

Everyone had a great time, this years event was well represented by The Houston Business Community.

Brought To You By Antiques of River Oaks Houston,Tx

Click to See Saving From Robert Graham Houston Galleria Store